Breaking News

Lonza Invests in Additional Bioconjugation Capabilities in Visp

The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related infrastructure to the existing bioconjugation facility.

Author Image

By: Charlie Sternberg

Associate Editor

Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, is investing in additional bioconjugation capabilities in Visp, Switzerland.   The expansion involves adding two 1,200L multipurpose manufacturing suites and related infrastructure to the current bioconjugation facility in Visp (CH) for both launch and commercial supply. This new capacity is projected to create around 200 jobs and is anticipated to be operational by 2028.   The new...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters